日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Disruption of gut barrier integrity and host-microbiome interactions underlie MASLD severity in patients with type-2 diabetes mellitus

肠道屏障完整性和宿主-微生物群相互作用的破坏是2型糖尿病患者合并酒精性脂肪肝(MASLD)严重程度的根本原因。

Forlano, R; Martinez-Gili, L; Takis, P; Miguens-Blanco, J; Liu, T; Triantafyllou, E; Skinner, C; Loomba, R; Thursz, M; Marchesi, J R; Mullish, B H; Manousou, P

Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis

循环生物标志物对非酒精性脂肪性肝炎的诊断性能

Arun J Sanyal, Sudha S Shankar, Katherine P Yates, James Bolognese, Erika Daly, Clayton A Dehn, Brent Neuschwander-Tetri, Kris Kowdley, Raj Vuppalanchi, Cynthia Behling, James Tonascia, Anthony Samir, Claude Sirlin, Sarah P Sherlock, Kathryn Fowler, Helen Heymann, Tania N Kamphaus, Rohit Loomba #, R

Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial

Aramchol治疗非酒精性脂肪性肝炎患者:一项随机、双盲、安慰剂对照的2b期试验

Ratziu, V; de Guevara, L; Safadi, R; Poordad, F; Fuster, F; Flores-Figueroa, J; Arrese, M; Fracanzani, Anna L; Ben Bashat, D; Lackner, K; Gorfine, T; Kadosh, S; Oren, R; Halperin, M; Hayardeny, L; Loomba, R; Friedman, S; Sanyal, Arun J

Current Concepts, Opportunities, and Challenges of Gut Microbiome-Based Personalized Medicine in Nonalcoholic Fatty Liver Disease

肠道微生物组在非酒精性脂肪肝疾病个性化治疗中的现状、机遇与挑战

Sharpton, S R; Schnabl, B; Knight, R; Loomba, R

Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis

非酒精性脂肪性肝炎中体重变化和奥贝胆酸相关的临床和代谢效应

Hameed, B; Terrault, N A; Gill, R M; Loomba, R; Chalasani, N; Hoofnagle, J H; Van Natta, M L

Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis

综述文章:非酒精性脂肪性肝炎治疗中新兴的抗纤维化疗法

Noureddin, M; Anstee, Q M; Loomba, R

Comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for non-invasive diagnosis of advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease: a prospective study

磁共振弹性成像与八项临床预测规则在经活检证实的非酒精性脂肪性肝病晚期纤维化无创诊断中的诊断准确性比较:一项前瞻性研究

Cui, J; Ang, B; Haufe, W; Hernandez, C; Verna, E C; Sirlin, C B; Loomba, R

Association between novel MRI-estimated pancreatic fat and liver histology-determined steatosis and fibrosis in non-alcoholic fatty liver disease

新型MRI估算的胰腺脂肪与非酒精性脂肪性肝病中肝脏组织学确定的脂肪变性和纤维化之间的关联

Patel, N S; Peterson, M R; Brenner, D A; Heba, E; Sirlin, C; Loomba, R

Solid-organ transplantation in older adults: current status and future research

老年人实体器官移植:现状与未来研究

Abecassis, M; Bridges, N D; Clancy, C J; Dew, M A; Eldadah, B; Englesbe, M J; Flessner, M F; Frank, J C; Friedewald, J; Gill, J; Gries, C; Halter, J B; Hartmann, E L; Hazzard, W R; Horne, F M; Hosenpud, J; Jacobson, P; Kasiske, B L; Lake, J; Loomba, R; Malani, P N; Moore, T M; Murray, A; Nguyen, M-H; Powe, N R; Reese, P P; Reynolds, H; Samaniego, M D; Schmader, K E; Segev, D L; Shah, A S; Singer, L G; Sosa, J A; Stewart, Z A; Tan, J C; Williams, W W; Zaas, D W; High, K P

Low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine response.

低剂量和标准剂量聚乙二醇干扰素α-2a治疗慢性丙型肝炎(基因型2或3):疗效、耐受性、病毒动力学和细胞因子反应

Rotman Y, Borg B B, Soza A, Feld J J, Modi A A, Loomba R, Lutchman G, Rivera E, Doo E, Ghany M G, Heller T, Neumann A U, Liang T J, Hoofnagle J H